Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Tenecteplase beats alteplase in real-world stroke outcomes. A large propensity-matched analysis found that tenecteplase used before mechanical thrombectomy in large vessel occlusion (LVO) stroke was linked to significantly lower 90-day mortality and fewer new speech and movement deficits — with no added bleeding risk. The findings align with current AHA/ASA guidelines supporting tenecteplase as a viable alternative to alteplase.
A real-world retrospective study using the TriNetX US Collaborative Network found that tenecteplase (TNK), used as bridging thrombolysis before mechanical thrombectomy for large vessel occlusion (LVO) stroke, outperformed alteplase on key 90-day outcomes. After propensity-score matching 2,322 patients per arm, TNK was associated with meaningfully lower mortality and fewer functional deficits — without a significant increase in symptomatic intracranial hemorrhage (sICH).
A secondary analysis of the BRIDGE-TNK trial adds nuance: tenecteplase's benefit before thrombectomy may depend on stroke cause. Patients with cardioembolic stroke saw improved functional independence with TNK, while those with large artery atherosclerosis did not — and even showed a trend toward higher mortality. Together, these findings suggest stroke etiology may be a key factor in treatment decisions.
By the Numbers:
Why it matters: These findings reinforce current AHA/ASA guidelines backing TNK as an alternative to alteplase before thrombectomy, while also signaling that stroke etiology could refine patient selection — a critical step toward more personalized acute stroke care.